Dear Cerulean Stockholder,
As the founder and CEO of Daré
The problem isn't a lack of early innovation. The global donor community of foundations and governments has invested in early research to expand options, improve outcomes and advance global women's health. Yet, promising candidates often fail to advance.
The problem isn't commercialization. Pharmaceutical companies with established sales and marketing franchises in women's health exist; however, many of these companies prefer to get involved in later stages of development, e.g., in pivotal trials or following an application for regulatory approval.
The problem is the gap in mid-stage development. We believe there is a gap between early innovation and commercialization in women's health that creates an opportunity for Daré.
Our business model is to fill the gap. We intend to license the rights to novel product candidates (some of which have existing clinical data), advance their clinical development and, if successful, create a comprehensive global commercialization strategy in combination with established pharmaceutical partners.
Our product candidate, Ovaprene®, illustrates our business model.
We intend to continue the clinical development of Ovaprene, which has
completed a pilot postcoital test clinical trial with results published
In connection with the proposed combination of Daré and Cerulean,
Cerulean has filed with the
If Cerulean stockholders approve the transactions in the proxy, the management of Daré looks forward to having the opportunity to work on your behalf.
If you have any questions regarding the proposed transactions, or to
obtain a copy of the definitive proxy statement free of charge, please
contact Cerulean's proxy solicitor,
Founder and CEO
The Cerulean Board unanimously recommends stockholders vote "FOR" all of the following proposals to be considered at the special meeting:
The full agenda for the special meeting is detailed in Cerulean's
definitive proxy statement, which has been filed with the
How to Vote
If you are a stockholder of record, you can vote your shares in one of two ways: either by proxy or in person at the special meeting. If you chose to submit a proxy, you may do so by telephone, via the internet or by mail. If you hold shares of Cerulean common stock in multiple accounts, you should vote your shares as described in each set of proxy materials you receive. Cerulean recommends stockholders vote electronically or by phone. Please have your proxy card with you while voting.
You may transmit your proxy voting instructions via the
For stockholders who still need assistance voting their shares, or have
questions regarding the special meeting, please contact Cerulean's proxy
Cerulean is a company previously focused on applying the Dynamic Tumor Targeting™ Platform to create nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations.
For more information on the company, please visit www.ceruleanrx.com.
About Daré Bioscience
Daré Bioscience is a healthcare company committed to the development and
commercialization of innovative products in women's reproductive health.
Daré believes there is an unmet need in
For more information on Daré, please visit www.darebioscience.com
Cautionary Note on Forward Looking Statements
This press release contains "forward-looking statements" regarding
matters that are not historical facts, including statements relating to
the expected timing and consummation of the transaction between Cerulean
and Novartis and between Cerulean, Daré, and the stockholders of Daré,
approval of the Novartis Transaction and Daré Transaction by Cerulean's
stockholders, the ability of the parties to satisfy other closing
conditions of the proposed transactions, Daré's expectations regarding
the timing and availability of results from its clinical trials, the
timing of commencement of manufacturing its products, and the safety and
effectiveness of its products. Because such statements are subject to
risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such as
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"hypothesize," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including: whether Cerulean's cash
resources will be sufficient to fund the operations of Daré it will
undertake following the closing; the uncertainties inherent in the
initiation and completion of clinical trials; availability and timing of
data from ongoing and future clinical trials and the results of such
trials; whether preliminary results from a clinical trial will be
predictive of the final results of that trial or whether results of
early clinical trials will be indicative of the results of later
clinical trials; whether the company will maintain its NASDAQ listing,
expectations for regulatory approvals; and other factors discussed in
the "Risk Factors" section of Cerulean's Quarterly Report on Form 10-Q
filed with the
News Provided by Acquire Media